用myo-inositol治疗并没有改善所有PCOS表现型的临床特征
Vittorio Unfer1,2, Michele Russo3, Cesare Aragona2,4
1UniCamillus-Saint Camillus International University of Health Sciences, 00131 Rome, Italy.
Biomedicines
|June 28, 2023
概括
在患有高雄性多囊卵巢综合征 (PCOS) 的女性中,myo-inositol (myo-Ins) 治疗显著改善了代谢和内分泌参数,但在非高雄性PCOS中显示出微不足道的影响. 特定于表型的治疗选择对于PCOS管理至关重要.
科学领域:
- 内分泌学 在内分泌学.
- 生殖医学 生殖医学
- 代谢健康 代谢健康
背景情况:
- 多囊卵巢综合征 (PCOS) 是一种复杂的内分泌疾病,影响生殖年龄的女性.
- 多囊性多囊性综合症呈现多种现象,需要量身定制的治疗策略.
- 肌肉内醇 (myo-Ins) 正在研究其在PCOS治疗中的潜在治疗益处.
研究的目的:
- 调查肌肉中毒醇 (myo-Ins) 治疗对各种多囊性卵巢综合征 (PCOS) 现象的差异性影响.
- 为了评估高雄性质是否影响PCOS患者对myo-Ins治疗的反应.
- 确定myo-Ins是否可以改善特定PCOS亚组中的代谢,内分泌和子宫内膜参数.
主要方法:
- 追溯性研究分析了PCOS患者,按表型分类 (A,B,C作为高雄性PCOS (H-PCOS);D作为非高雄性PCOS (NH-PCOS)).
- 患者接受了6个月的myo-inositol (myo-Ins) 治疗.
- 在H-PCOS和NH-PCOS组之间比较治疗反应.
主要成果:
- 米奥伊诺西托 (myo-Ins) 给药导致了代谢和内分泌参数的显著改善,特别是在高雄性PCOS (H-PCOS) 组.
- 在非高雄性PCOS (NH-PCOS) 组中观察到myo-Ins的微不足道影响.
- 用myo-Ins治疗也改善了H-PCOS患者的子宫内膜厚度.
结论:
- 多囊性卵巢综合征 (PCOS) 患者对myo-inositol (myo-Ins) 治疗的反应因其特定的表型而异.
- 肌体内治疗的疗效受到高雄性特征存在的显著影响.
- 区分PCOS表型对于优化治疗方法和改善患者治疗结果至关重要.
相关概念视频
02:07Oogenesis
63.9K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
63.9K
01:28Infertility in Females
353
Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of...
Endometriosis, a condition characterized by abnormal growth of...
353
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
199
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
199
01:30Hormonal Control of the Ovarian Cycle
592
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
592
01:42Phosphoinositides and PIPs
8.6K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.6K
01:21Drugs for Treatment of Constipation-Predominant IBS
230
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
230